Treatment thresholds for intervention in posthaemorrhagic ventricular dilation: a randomised controlled trial.


Journal

Archives of disease in childhood. Fetal and neonatal edition
ISSN: 1468-2052
Titre abrégé: Arch Dis Child Fetal Neonatal Ed
Pays: England
ID NLM: 9501297

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 02 10 2017
revised: 13 01 2018
accepted: 15 01 2018
pubmed: 15 2 2018
medline: 8 1 2019
entrez: 15 2 2018
Statut: ppublish

Résumé

To compare a low versus a higher threshold for intervention in preterm infants with posthaemorrhagic ventricular dilatation. Multicentre randomised controlled trial (ISRCTN43171322). 14 neonatal intensive care units in six countries. 126 preterm infants ≤34 weeks gestation with ventricular dilatation after grade III-IV haemorrhage were randomised to low threshold (LT) (ventricular index (VI) >p97 and anterior horn width (AHW) >6 mm) or higher threshold (HT) (VI>p97+4 mm and AHW >10 mm). Cerebrospinal fluid tapping by lumbar punctures (LPs) (max 3), followed by taps from a ventricular reservoir, to reduce VI, and eventually a ventriculoperitoneal (VP) shunt if stabilisation of the VI below the p97+4 mm did not occur. VP shunt or death. 19 of 64 (30%) LT infants and 23 of 62 (37%) HT infants were shunted or died (P=0.45). A VP shunt was inserted in 12/64 (19%) in the LT and 14/62 (23%) infants in the HT group. 7/12 (58%) LT infants and 1/14 (7%) HT infants required shunt revision (P<0.01). 62 of 64 (97%) LT infants and 36 of 62 (58%) HT infants had LPs (P<0.001). Reservoirs were inserted in 40 of 64 (62%) LT infants and 27 of 62 (43%) HT infants (P<0.05). There was no significant difference in the primary composite outcome of VP shunt placement or death in infants with posthaemorrhagic ventricular dilatation who were treated at a lower versus a higher threshold for intervention. Infants treated at the lower threshold received more invasive procedures. Assessment of neurodevelopmental outcomes will provide further important information in assessing the risks and benefits of the two treatment approaches.

Identifiants

pubmed: 29440132
pii: archdischild-2017-314206
doi: 10.1136/archdischild-2017-314206
doi:

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

F70-F75

Investigateurs

Han K (H)
Steggerda S (S)
Benders Mjnl (B)
Dudink J (D)
Ter Horst Hj (TH)
Dijkman Kp (D)
Ley D (L)
Fellman V (F)
De Haan Tr (H)
Agut Quijano T (AQ)
Barcik U (B)
Mathur A (M)
Graca Am (G)

Informations de copyright

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Linda S de Vries (LS)

Department of Neonatology and Brain Center Rudolf Magnus, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.

Floris Groenendaal (F)

Department of Neonatology and Brain Center Rudolf Magnus, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.

Kian D Liem (KD)

Department of Neonatology, Amalia Children's Hospital, Radboud University Medical Center, Nijmegen, The Netherlands.

Axel Heep (A)

Department of Neonatology, Southmead Hospital, School of Clinical Science, University of Bristol, Bristol, UK.

Annemieke J Brouwer (AJ)

Department of Neonatology and Brain Center Rudolf Magnus, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.
University of Applied Sciences Utrecht, Utrecht, The Netherlands.

Ellen van 't Verlaat (E)

University of Applied Sciences Utrecht, Utrecht, The Netherlands.
Department of Neonatology, Erasmus Medical Center, Rotterdam, The Netherlands.

Isabel Benavente-Fernández (I)

Neonatology Department, 'Puerta del Mar' University Hospital, Cadiz, Spain.

Henrica Lm van Straaten (HL)

Isala Women and Children's Hospital, Zwolle, The Netherlands.

Gerda van Wezel-Meijler (G)

Isala Women and Children's Hospital, Zwolle, The Netherlands.
Department of Neonatology, Leiden University Medical Center, Leiden, The Netherlands.

Bert J Smit (BJ)

Directorate Quality & Patientcare, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Paul Govaert (P)

Department of Neonatology, Erasmus Medical Center, Rotterdam, The Netherlands.

Peter A Woerdeman (PA)

Division of Neuroscience, Department of Neurosurgery, University Medical Center Utrecht, Utrecht, The Netherlands.

Andrew Whitelaw (A)

Department of Neonatology, Southmead Hospital, School of Clinical Science, University of Bristol, Bristol, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH